ASCO
Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
Premium
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
The company recently presented data on the use of its spectroscopic liquid biopsy test for the early-stage detection of multiple cancers at ASCO.
New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur
Premium
Investigators shared results of a study this week in which ctDNA residual disease testing gave advance notice of late recurrences in surgically resected HR+ HER2- patients.
Researchers reported prospective randomized trial data showing non-inferiority of adjuvant treatment guided by minimal residual disease testing.
InterVenn BioSciences Hits Commercial Phase, Launches Test for Immunotherapy Response in Melanoma
Premium
At the ASCO meeting this week, the firm will present validation data on the test, which predicts response to immune checkpoint inhibitors in advanced melanoma.